Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once-Weekly Eloralintide in Adult Participants With Obesity or Overweight, Type 2 Diabetes, and Increased CV Risk
NCT07900633 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once-Weekly Eloralintide in Adult Participants With Obesity or Overweight, Type 2 Diabetes, and Increased CV Risk
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- December 31, 2026
- Completion date
- December 31, 2029
- Enrollment
- 3,000 (estimated)
- Sites
- 309
Conditions
As the registry lists them; a condition with its own page is linked.
Lead sponsor's other trials
Eli Lilly and Company, most recent start first.
+2,100 more trials See the organization page
Similar trials
Same condition (Diabetes Mellitus, Type 2) and phase, most recent start first.
+1,316 more trials See the condition page